$41.01
-2.67 (-6.11%)
Open$42.05
Previous Close$43.68
Day High$44.21
Day Low$40.94
52W High$47.84
52W Low$2.81
Volume—
Avg Volume536.2K
Market Cap2.71B
P/E Ratio—
EPS$-4.32
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-68.8% upside
Current
$41.01
$41.01
Target
$12.80
$12.80
$8.80
$12.80 avg
$18.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 639.02M | 671.15M | 526.83M |
| Net Income | 3.07M | 3.06M | 2.31M |
| Profit Margin | 0.5% | 0.5% | 0.4% |
| EBITDA | 3.98M | 4.67M | 3.27M |
| Free Cash Flow | 2.86M | 3.84M | 2.49M |
| Rev Growth | +2.1% | +18.5% | -6.0% |
| Debt/Equity | 0.55 | 0.45 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |